Skip to content
Screener

Pfizer PFE Q4 2025 Annual earnings

Reported February 3, 2026 · Before market open

Revenue$17.6BBeat by $708.1M
EPS$0.66Beat by $0.09
Revenue estimate$16.8B
EPS estimate$0.57

Next report

Nov 3, 2026 (in a month)
Revenue estimate$15.9B
EPS estimate$0.77

Financials

Q4 2025

Income statement

See full
Revenue$17.6B-1.2%
Gross profit$12.3B+3.6%

Balance sheet

See full
Cash & equivalents$1.2B+8.1%
Total debt$67.3B+5.4%
Total equity$86.5B-2.0%
Total assets$208.16B-2.5%

Cash flow

See full
Operating cash flow$5.3B-20.4%
CapEx$845.0M-7.9%
Free cash flow$4.5B-22.4%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$141.57B-5.8%
Enterprise value$207.64B-2.5%
P/S2.3×-0.1×

Profitability

See full
Gross margin74.3%+2.4pp

Returns & leverage

See full
Debt / equity0.8×+0.1×
Current ratio1.2×0.0×

Segments

By product

See full
Comirnaty$2.3B-32.9%
Eliquis$2.0B+10.3%
Prevnar Family$1.7B+9.6%
Vyndaqel family$1.7B+9.3%
Ibrance$1.0B-5.1%

By segment

See full
Biopharma$17.1B-1.6%

By geography

See full
International Emerging Markets$2.5B+11.4%

FAQ

When did Pfizer report Q4 2025 earnings?
Pfizer (PFE) reported Q4 2025 earnings on February 3, 2026 before market open.
What were Pfizer's Q4 2025 revenue and EPS?
Pfizer reported revenue of $17.6B and eps of $0.66 for Q4 2025.
Did Pfizer beat estimates in Q4 2025?
Revenue beat the consensus estimate of $16.8B by $708.1M. EPS beat the consensus estimate of $0.57 by $0.09.
How did Pfizer's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 1.2% from $17.8B a year earlier and eps grew 4.8% from $0.63.
Where can I find Pfizer's Q4 2025 SEC filings?
You can read the 8-K earnings release (0000078003-26-000005) and the 10-K periodic report (0000078003-26-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.